A randomized, double-blind, placebo-controlled phase IIIa study on bIAP, an anti-inflammatory moiety, in patients undergoing combined aortic valve replacement and coronary artery bypass grafting.
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Alkaline phosphatase (Primary)
- Indications Ischaemia; Reperfusion injury
- Focus Therapeutic Use
- Acronyms APPIRED II
- Sponsors Alloksys Life Sciences
- 13 Jan 2014 New trial record